Cures Act implementation: Gottlieb says faster cancer drug approvals coming for secondary indications
FDA Commissioner Scott Gottlieb and NIH Director Francis Collins testified on Thursday before the House Energy & Commerce Committee on how their agencies have worked to implement provisions from the 21st Century Cures Act passed and signed by President Barack Obama a month before he left office.
The hearing centered on the mammoth new law that includes major tweaks to how FDA regulates drugs, devices and biologics, and provides the agency with $500 million over 10 years to implement it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
